TCTAP 2018

PARTNER 2A and SAPIEN 3 Cost-Effectiveness: Cost-effectiveness of TAVR Versus SAVR in Intermediate Risk Patients with Aortic Stenosis

- Presenter : David Joel Cohen

Leave a comment

Sign in to leave a comment.